Edgewise Therapeutics agreed to sell its muscular dystrophy business and Sevasemten to Servier for $1.55 billion in cash, plus up to $1.1 billion in additional potential payments. The transaction is a major value-realization event for the biotech and meaningfully reshapes its asset portfolio. The size of the deal makes it likely to be material for the stock and relevant across the biotech M&A space.
Edgewise Therapeutics agreed to sell its muscular dystrophy business and Sevasemten to Servier for $1.55 billion in cash, plus up to $1.1 billion in additional potential payments. The transaction is a major value-realization event for the biotech and meaningfully reshapes its asset portfolio. The size of the deal makes it likely to be material for the stock and relevant across the biotech M&A space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
